JPY5,043.00
3.02% today
Tokyo, Sep 19, 02:10 am CET
ISIN
JP3475350009
Symbol
4568
Index
Sector
Industry

DAIICHI SANKYO Stock price

JPY4,895.00
-871.00 15.11% 1M
-41.00 0.83% 6M
+1,023.00 26.42% YTD
+772.00 18.72% 1Y
+2,090.50 74.54% 3Y
+2,551.00 108.83% 5Y
+4,288.50 707.09% 10Y
Tokyo, Closing price Wed, Sep 18 2024
-73.00 1.47%
ISIN
JP3475350009
Symbol
4568
Index
Sector
Industry

Key metrics

Market capitalization JPY9.35t
Enterprise Value JPY8.64t
P/E (TTM) P/E ratio 40.94
EV/FCF (TTM) EV/FCF 19.18
EV/Sales (TTM) EV/Sales 5.12
P/S ratio (TTM) P/S ratio 5.54
P/B ratio (TTM) P/B ratio 5.43
Dividend yield 1.21%
Last dividend (FY25) JPY60.00
Revenue growth (TTM) Revenue growth 25.06%
Revenue (TTM) Revenue JPY1.69t
EBIT (operating result TTM) EBIT JPY206.07b
Free Cash Flow (TTM) Free Cash Flow JPY450.50b
Cash position JPY805.26b
EPS (TTM) EPS JPY119.55
P/E forward 45.15
P/S forward 5.23
EV/Sales forward 4.84
Show more

Is DAIICHI SANKYO a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

DAIICHI SANKYO Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a DAIICHI SANKYO forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a DAIICHI SANKYO forecast:

Buy
87%
Hold
13%

Financial data from DAIICHI SANKYO

Jun '24
+/-
%
Net Profit 85,383 85,383
50% 50%
20%
Depreciation and Amortization 16,615 16,615
17% 17%
4%
Stock Compensation - -
-
-
Operating Cash Flow -110,042 -110,042
138% 138%
-25%
Investments 32,012 32,012
21% 21%
7%
Dividend Paid 57,570 57,570
100% 100%
13%
Free Cash Flow -131,221 -131,221
85% 85%
-30%

In millions JPY.

Don't miss a Thing! We will send you all news about DAIICHI SANKYO directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Head office Japan
CEO Sunao Manabe
Employees 18,726
Founded 2005
Website www.daiichisankyo.co.jp

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today